PINE BROOK, N.J., June 21 /PRNewswire/ -- Elusys Therapeutics, Inc.
(Elusys), a privately-held biopharmaceutical company developing
antibody-based therapies for the treatment of life-threatening infectious
diseases, today announced it has expanded its senior management team with
the appointment of Jeremy D. Middleton as Vice President of Corporate
Development.
Elizabeth Posillico, Ph.D., President and Chief Executive Officer of
Elusys commented on the appointment, "We are very excited that Jerry has
joined our team. He brings a terrific breadth and depth of business
development, strategic planning and project management skills. His new
product commercialization experience will be of great benefit to Elusys.
Jerry will initially focus on the many commercial opportunities for our
technology."
Mr. Middleton added, "Elusys has partnered with MedImmune and Pfizer on
collaborative research and license agreements. Partnering with two of the
world's top biotech and pharmaceutical companies is a real validation of
Elusys' HP Antibody(TM) technology and the company as a whole. HP
Antibodies are truly a novel approach to treating a wide variety of serious
infectious diseases and there are numerous commercial opportunities for
this unique platform."
Mr. Middleton is a biopharmaceutical executive with more than 20 years
international experience. Prior to joining Elusys, he was Vice President of
Business Development at Valera Pharmaceuticals, Inc., before its merger
with Indevus Pharmaceuticals, Inc. During his tenure with Valera, he was
responsible for developing corporate strategies to identify and access new
market opportunities. Mr. Middleton also played a lead role in negotiating
the recent merger with Indevus.
Mr. Middleton was previously a Vice President at Neose Technologies,
Inc., a clinical-stage biopharmaceutical company focused on the development
of next-generation therapeutic proteins. At Neose, he directed business
strategy, commercial development, manufacturing and facilities functions.
Formerly, he was Global Product Director for Immunology at Abbott
Laboratories/BASF Pharma. Mr. Middleton earned his Bachelor of Science in
Applied Chemistry from De Montfort University, Leicester, England.
About Elusys' HP Antibody(TM) Technology
HP Antibodies represent a new approach for the treatment of antibiotic
resistant infections distinct from traditional antibody therapy. HP
Antibodies utilize natural immune system mechanisms to clear pathogens and
provide a means to develop novel drug candidates targeted against
bacterial, viral and fungal infections. By targeting a unique immune
receptor, HP Antibodies enhance a natural clearance mechanism and direct
the rapid removal of pathogens from the circulation to tissue macrophages.
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the
development of antibody-based therapeutics for the treatment of
life-threatening infectious disease. In March of 2007, the company's
anthrax antibody therapeutic, Anthim(TM), was selected to R&D Directions'
list of "100 Great Investigational Drugs."
Current venture investors include Essex Woodlands Health Ventures LLC,
Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer.
For more information please visit http://www.elusys.com.
SOURCE Elusys Therapeutics, Inc.
 back to top
Related links:
http://www.elusys.com
CONTACT:
Bryan P. Murphy, of LaVoie Group,
+1-978-745-4200 X 105, bmurphy@lavoiegroup.com, for Elusys
Therapeutics, Inc.
|
